Caution is needed when interpreting changes of matrix metalloproteinase-3 in patients with rheumatoid arthritis

被引：0

作者：

Nagashima, Takao ^{[1
]}

Minota, Seiji ^{[1
]}

机构：

[1] Jichi Med Univ, Div Rheumatol & Clin Immunol, Dept Med, Shimotsuke, Tochigi 3290498, Japan

来源：

RHEUMATOLOGY INTERNATIONAL | 2014年 / 34卷 / 07期

关键词：

Rheumatoid Arthritis; Rheumatoid Arthritis Patient; Synovitis; Tocilizumab; Disease Activity Score;

D O I：

10.1007/s00296-013-2837-6

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1025 / 1026

页数：2

共 6 条

[1] Clinical results for tocilizumab over one year in the clinical setting as assessed by CDAI (clinical disease activity index): CRP at week 12 and MMP-3 at week 24 are predictive factors for CDAI [J].

Kaneko, Atsushi ;

Kida, Daihei ;

Saito, Kiwamu ;

Tsukamoto, Masami ;

Sato, Tomotaro .

RHEUMATOLOGY INTERNATIONAL, 2012, 32 (11) :3631-3637

[2] Comment on: Usefulness of anti-cyclic citrullinated peptide antibody and rheumatoid factor to detect rheumatoid arthritis in patients with systemic sclerosis [J].

Nagashima, Takao ;

Minota, Seiji .

RHEUMATOLOGY, 2011, 50 (05) :994-996

[3] Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment [J].

Ribbens, C ;

Porras, MMY ;

Franchimont, N ;

Kaiser, MJ ;

Jaspar, JM ;

Damas, P ;

Houssiau, FA ;

Malaise, MG .

ANNALS OF THE RHEUMATIC DISEASES, 2002, 61 (02) :161-166

[4]

Sharif M, 1998, ARTHRITIS RHEUM-US, V41, P1203, DOI 10.1002/1529-0131(199807)41:7<1203::AID-ART9>3.0.CO

[5]

2-2

[6]

Shinozaki Mikiko, 2007, Mod Rheumatol, V17, P403, DOI 10.1007/s10165-007-0608-5

← 1 →